Professional Documents
Culture Documents
Sindrome Hepatorenal PDF
Sindrome Hepatorenal PDF
The onset of renal failure in a patient with cirrhosis or acute liver failure
(ALF, also known as fulminant liver failure) is alarming because it raises
the possibility of the hepatorenal syndrome (HRS). HRS is a distinct form
of renal failure that occurs in the setting of severe liver disease. HRS is the
most frequently fatal complication of cirrhosis, because nearly half of patients die within 2 weeks of this diagnosis (Fig. 1) [1]. The annual incidence
of HRS is estimated at 8% to 40% in cirrhosis [2,3]. The Model for End
Stage Liver Disease (MELD) score [46] in patients with cirrhosis and ascites parallels the risk of developing HRS [3,7]. Onset of ascites in patients
with MELD scores of about 10 is associated with an 8% and 11% risk of
HRS at 1 and 5 years, respectively [7]. If the MELD score approaches 18,
nearly 40% of patients develop HRS within 1 year [3]. The frequency of
HRS in severe acute alcoholic hepatitis and in fulminant liver failure is
about 30% and 55%, respectively [8,9]. Most episodes of renal failure in
patients with liver disease, however, are not related to HRS. Common
high-risk scenarios for HRS include diuretic-resistant tense ascites, severe
hyponatremia or coagulopathy, and a MELD score greater than 18. Profound jaundice is often present, but HRS can develop in patients with
minimal hyperbilirubinemia. Periodic surveillance of renal function is helpful in patients with severe liver disease to detect HRS early and to help
correct reversible contributing factors. Once established, HRS responds
relatively poorly to medical management, although recent advances have
brought hope for an improved prognosis. In this article, the diagnosis,
814
MUNOZ
Fig. 1. Severe impact on survival associated with onset of hepatorenal syndrome. (From Arroyo
V, Terra C, Gines P. Advances in the pathogenesis and treatment of type 1 and type-2 hepatorenal
syndrome. J Hepatol 2007;45:93546; with permission.)
815
816
MUNOZ
817
818
MUNOZ
uropathy; shock; drug-induced renal failure; and intrinsic renal disease (eg,
hepatitis Crelated chronic glomerulonephritis, diabetic nephropathy). It is
critical to ensure an adequate intravascular volume by discontinuing diuretics and expanding the plasma volume. A signicant improvement in renal function (serum creatinine) after these maneuvers is inconsistent with
HRS. Plasma volume expansion was previously accomplished by intravenous administration of 1.5 L of normal saline [10], but sodium chloride
can readily escape from the intravascular compartment, particularly in patients with severe hypoalbuminemia (!22.5 g/dL), and minimally expands
the intravascular volume. Intravenous albumin (1 g/kg body weight up to
100 g) is now used (with packed erythrocytes if concomitant severe anemia
is present) because of greater ecacy in volume expansion and in achieving
a sustained reduction in serum creatinine [11]. In one study, 55% of patients
with HRS who failed a trial of volume expansion with isotonic saline had
reversal of HRS following albumin administration alone [21]. Patients
who respond to volume expansion with albumin do not have HRS, but renal
failure from hypovolemia. If renal failure persists after vigorous volume replacement with colloids, HRS is likely. A history of recent shock or administration of nephrotoxic agents, imaging evidence of urinary obstruction or
scarred kidneys, and a urinary sediment consistent with glomerular disease
suggest etiologies other than HRS. If intrinsic renal disease is identied, the
dilemma consists of determining whether the kidney disease is the sole cause
of the renal failure, or whether HRS is a contributing factor (type 3 HRS).
Infections (particularly spontaneous bacterial peritonitis, but also sepsis,
cellulitis, urinary tract infection, or pneumonia) can cause transient renal
dysfunction in cirrhotics that typically resolves with control of the infection.
Infections can, however, precipitate type 1 HRS (see later). This scenario is
suspected when the renal failure persists or worsens despite resolution of the
infection. Nonoliguric HRS (urine volumes O500 mL per 24 hours) and
HRS with urinary sodium excretion greater than 10 mEq/L can occasionally
occur [2224].
Pathophysiology
Type 1 hepatorenal syndrome
A series of clinical and experimental studies during the last two decades
has considerably increased the understanding of the pathophysiology of
HRS (Figs. 2, 3) [11,2527]. Hepatic brosis, architectural distortion, and
inammation from hepatic injury result in portal hypertension that is generally progressive. Both chronic liver disease and ALF can cause portal hypertension. Portal hypertension leads to arterial vasodilatation and pooling of
blood in the splanchnic bed, with a decrease in systemic vascular resistance.
In response, a systemic hyperdynamic circulatory state develops. Eventually,
activation of the renin-angiotensin-aldosterone system and the sympathetic
819
Central
hypovolemia
Decrease in
cardiac output
Increase in arterial
vasodilation
Impaired cardiac
chronotropic function
Reduction in effective
arterial blood volume
moderate
severe
extreme
Sodium
retention
Water retention
Hyponatremia
Hepatorenal
syndrome
Fig. 2. Pathophysiology of the hepatorenal syndrome. (From Arroyo V, Terra C, Gine`s P. New
treatments of hepatorenal syndrome. Semin Liver Dis 2006;26:25464; with permission.)
820
MUNOZ
Aggravation of
portal hypertension
Regional arterial
vasoconstriction
Kidneys
HRS
Brain
Encephalopathy
Liver
Liver failure
cirrhotics with sepsis and adrenal insuciency improved systemic hemodynamics and in-hospital survival [34]. The arterial response to endogenous
vasoconstrictors depends on adequate levels of adrenal corticosteroid
hormones. Adrenal dysfunction may be important in the hemodynamic
mechanism of type 1 HRS related to sepsis.
The precipitating event for type 1 HRS is believed rapidly to worsen the
hemodynamic disturbances that led to acute renal failure. The magnitude
and pace of circulatory derangement induced by this precipitating event
may exceed a threshold beyond which the hepatic, brain, and adrenal vascular beds join with the renal vasculature in vasoconstriction, which results in
multiorgan failure (see Fig. 3) [11]. Conceptual dierences between HRS
types 1 and 2 have clinical implications for the prevention of HRS and
the management of precipitating events.
Type 2 hepatorenal syndrome
The hemodynamic and humoral abnormalities described previously for
type 1 HRS also operate in type 2 HRS, but are present to a lesser extent.
Type 2 HRS is related to gradually deteriorating liver function that results
in circulatory dysfunction. In contrast to type 1 HRS, precipitating factors
are generally not present in type 2 HRS. Many patients with type 2 HRS eventually progress to type 1 HRS, however, often because of a precipitating event.
A better understanding of circulatory abnormalities associated with HRS
has led to a combination of therapeutic interventions to correct these abnormalities (ie, the decreased intravascular eective arterial volume, the renal
vasoconstriction, and the peripheral arterial vasodilatation).
821
822
MUNOZ
823
824
MUNOZ
Table 1
Eect of noradrenaline and albumin versus terlipressin and albumin in hepatorenal syndrome
Baseline
End of therapy
Baseline
End of therapy
2.3 0.2
71 2
1.3 0.1a
84 2a
2.5 0.3
74 3
1.3 0.2a
84 3a
11 1
12 1
12 1
13 3
788 84
26 1
15 3
1583 243a
24 2
93
698 113
26 2
21 5
1578 314a
20 2a
7 3a
About 12 pilot studies conducted during the last decade have suggested
that vasopressor therapy plus intravenous albumin improves the prognosis
of HRS. The total number of studied patients is less than 250, however,
and the results may be subject to sampling bias because of inconsistent study
inclusion criteria [54,55]. Nevertheless, prudent use of this combined therapy
seems justied in type 1 HRS given the consistently reported benets in the
context of the otherwise rapidly fatal outcome of type 1 HRS. In some reports, responders to vasoconstrictor plus albumin therapy had improved
survival, and a signicant proportion of patients were successfully bridged
to liver transplantation [5660]. Patients with type 1 HRS typically have
825
826
MUNOZ
For patients whose HRS reversed with terlipressin and albumin, the
prognosis after liver transplantation is excellent and similar to that of transplanted patients without HRS [57]. The rate of postoperative hemodialysis,
severe infections, bleeding complications, recurrence of renal failure, and
survival and the mean hospital length of stay are similar to recipients transplanted without HRS [57]. Limitations of terlipressin therapy include a failure to reverse HRS in 40% to 45% of patients, high cost, and a high rate of
HRS recurrence after treatment discontinuation. Terlipressin cannot be
used in patients with vascular disorders (see Box 4). It is presently unavailable in the United States. Where available, terlipressin plus albumin therapy
seems relatively safe, well tolerated, and able to reverse the renal failure in
about half of treated patients. Additional studies are necessary to optimize
this therapy [54,55].
Noradrenaline plus albumin
Intravenous noradrenaline plus albumin has been evaluated as a therapy
for HRS in countries where terlipressin is unavailable. Alessandria and
827
828
MUNOZ
829
830
MUNOZ
831
choice for either type of HRS. Indeed, many reports have demonstrated resolution of HRS and long-term survival following liver transplantation.
Patients with HRS undergoing liver transplantation, however, have a slightly
increased perioperative morbidity and mortality compared with transplanted patients without HRS [8588]. Nevertheless, HRS is not a contraindication to liver transplantation. Allocation of liver donors is now primarily
guided by the MELD score, an index of disease severity and indicator of
short-term prognosis [46]. Serum creatinine is the highest weighted factor
in calculating the MELD score. Patients with HRS, particularly type 1, frequently achieve the highest priority for donor organ allocation. Despite
their generally high priority, patients with HRS often are not transplanted.
The precipitating event, such as SBP or sepsis, may prevent transplant surgery [36,37]. Additionally, type 1 HRS patients are often extremely ill, with
multiorgan failure, in whom the risks of transplant surgery may be prohibitive. In regions with a severe shortage of liver donors, the progression of
type 1 HRS within several weeks may provide insucient time to receive
a donor liver. In contrast, liver transplantation may be more practical and
successful in type 2 HRS, because of an absence of precipitating events,
its longer clinical course, and the relatively less severe renal failure. Patients
with any type of HRS have a very poor short-term prognosis without liver
transplantation [15]. They should have the highest priority for liver allocation, even if this requires requesting an exception to upgrade the MELD
score.
With MELD scores governing liver allocation, more patients with simultaneous liver and renal failure are achieving a high priority for transplantation. An important dilemma is whether to transplant both the liver and the
kidney in these extremely ill patients. Some patients have HRS, whereas
others have coexisting intrinsic renal disease (type 3 HRS; see Box 1). These
mixed clinical syndromes include chronic renal failure plus HRS, and nonHRS acute renal failure (ATN) plus simultaneous HRS. Determining the
diagnostic category in a specic patient is complex and requires urgent consultation by a team consisting of a hepatologist, nephrologist, and liver
transplant surgeon because of the poor short-term prognosis of HRS.
This determination should be done as expeditiously and as precisely as possible given the time constraints. Liver transplantation without renal transplantation is the best choice for patients with pure forms of HRS, and
perhaps in those with HRS and ATN, given the prospects of recovery
with postoperative RRT. Two recent reports found a possible benet of
combined liver-kidney transplantation in HRS patients selected on the basis
of requirement for RRT for longer than 8 weeks [89,90]. Simultaneous liverkidney transplantation may be the preferred approach for HRS in a patient
with chronic renal failure or with ATN superimposed on chronic renal
failure. Unfortunately, little data are available on these combined clinical
scenarios. Several large studies have reported the outcomes of patients
with elevated serum creatinine undergoing liver transplantation, but these
832
MUNOZ
studies did not report the proportion of patients with HRS, chronic renal
failure, ATN, or combinations thereof [91]. Cohorts with elevated serum
creatinine include dierent types of renal dysfunction [89].
The success of vasoconstrictor therapy for HRS in liver transplant candidates is important. Reversal of HRS before liver transplantation lowers the
postoperative risks of severe infections, bleeding complications, need for
hemodialysis, and recurrence of renal failure, while improving survival
and shortening postoperative hospital length of stay [57].
After liver transplantation, patients with HRS slowly recover renal function. The persistent postoperative renal impairment frequently requires
decreasing the dosage of calcineurin inhibitors (cyclosporine A, tacrolimus),
or renal-sparing immunosuppressive protocols.
Prevention of hepatorenal syndrome
Sepsis, variceal hemorrhage, shock, severe acute alcoholic hepatitis, or
use of nephrotoxic drugs often precipitate type 1 HRS. The risk of HRS
may be lowered by following standard guidelines to prevent these events,
particularly SBP or variceal bleeding [18,38]. Infections other than SBP
should be promptly identied and vigorously treated to minimize the risk
of HRS. Debilitated patients with advanced cirrhosis often have chronic
leukopenia and may not develop leukocytosis or fever, even with severe
infections. A high index of suspicion is necessary to identify infections early
in decompensated cirrhotics.
Prevention of type 1 HRS has been demonstrated in three prospective
randomized clinical trials [3,92,93]. In the most recent trial, administration
of noroxacin for primary prophylaxis for SBP reduced the 1-year probability of HRS to 28%, compared with 41% in controls not administered antibiotic prophylaxis (Fig. 5) [3]. This study strongly suggested that HRS can
be prevented in patients with advanced cirrhosis and ascites with a low
protein content (!1.5 g/dL). In another study, the administration of albumin (1 g/kg intravenously) at diagnosis and at day 3 in patients with SBP
signicantly reduced the incidence of type 1 HRS and the 3-month mortality
[92]. Administration of pentoxifylline, 400 mg three times a day, to patients
with severe acute alcoholic hepatitis was associated with a marked reduction
in HRS incidence and in-hospital mortality [93]. A recent prospective controlled trial, however, failed to conrm these benets [94]. Prevention of
HRS by use of antibiotic prophylaxis for SBP [3], or of albumin for SBP
[92], in patients with liver failure or acute alcoholic hepatitis [94] has not
yet been conrmed by subsequent large studies. The magnitude of these
eects in the context of the otherwise poor prognosis of HRS, however,
has led to broad acceptance of these prophylactic measures.
Specic preventive measures for type 2 HRS have not been identied. Patients developing this variant of HRS do not usually have precipitating
events. Because type 2 HRS is often associated with tense refractory ascites
833
834
MUNOZ
[11] Arroyo V, Terra C, Gines P. Advances in the pathogenesis and treatment of type 1 and type-2
hepatorenal syndrome. J Hepatol 2007;46:93546.
[12] Salerno F, Gerbes A, Gine`s P, et al. Diagnosis, prevention and treatment of hepatorenal
syndrome in cirrhosis. Gut 2007;56:13108.
[13] Portal A, Bruce M, Austin M, et al. Renal dysfunction following liver transplantation:
a comparison of novel renal biomarkers in the post transplant period. Hepatology 2007;
46(Suppl 1):501A.
[14] Portal AJ, Austin M, Heneghan MA. Novel approaches to assessing renal function in
cirrhotic liver disease. Hepatol Res 2007;37(9):66772.
[15] Alessandria C, Ozdogan O, Guevara M, et al. MELD score and clinical type predict prognosis
in hepatorenal syndrome: relevance to liver transplantation. Hepatology 2005;41:12829.
[16] McGuire B, Julian B, Bynon S, et al. Brief communication: glomerulonephritis in patients
with hepatitis C cirrhosis undergoing liver transplantation. Ann Intern Med 2006;144:
73541.
[17] McGuire B, Julian B, Novak J, et al. High prevalence of glomerulonephritis in patients with
end-stage HCV-induced cirrhosis. Hepatology 2007;46(Suppl 1):474A.
[18] Runyon B. AASLD Practice Guideline: management of adult patients with refractory
ascites. Hepatology 2004;39:84156.
[19] Servin-Abad L, Regev A, Contreras G, et al. Retrospective analysis of 140 patients labeled as
hepatorenal syndrome in a referral center. Hepatology 2005;42(4 Suppl 1):543A.
[20] Watt K, Uhanova J, Minuk GY. Hepatorenal syndrome: diagnostic accuracy, clinical
features and outcome in a tertiary care center. Am J Gastroenterol 2002;97:204650.
[21] Peron JM, Bureau C, Gonzalez L, et al. Treatment of hepatorenal syndrome as dened by
the international ascites club by albumin and furosemide infusion according to the central
venous pressure: a prospective pilot study. Am J Gastroenterol 2005;100:27027.
[22] Wong F, Pantea L, Sniderman K, et al. Midodrine, octreotide, albumin, and TIPS in
selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004;40:
5564.
[23] Duvoux C, Zanditenas D, Hezode C, et al. Eects of noradrenaline and albumin in patients
with type 1 hepatorenal syndrome: a pilot study. Hepatology 2002;36:37480.
[24] Dudley F, Kanel G, Wood L, et al. Hepatorenal syndrome without avid sodium retention.
Hepatology 1986;6:24851.
[25] Wadei HM, Mai ML, Ashan N, et al. Hepatorenal syndrome: pathophysiology and management. Clin J Am Soc Nephrol 2006;1:106679.
[26] Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal
syndrome in cirrhosis. Hepatology 2005;42:43947.
[27] Ruiz-del-Arbol W, Urman J, Fernandez J, et al. Systemic, renal, and hepatic hemodynamic
derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003;
38:12108.
[28] Schroeder E, Eich R, Smulyan H, et al. Plasma renin in hepatic cirrhosis: relation to functional renal failure. Am J Med 1970;49:18691.
[29] Arroyo V, Planas R, Gaya J, et al. Sympathetic nervous activity, renin-angiotensin system
and renal excretion of prostaglandin-E2 in cirrhosis: relationship to functional renal failure,
and sodium and water excretion. Eur J Clin Invest 1983;13:2718.
[30] Rimola A, Gines P, Arroyo V, et al. Urinary excretion of 6-keto prostaglandin F1-alpha,
thromboxane B-2 and prostaglandin E2 in cirrhosis with ascites: relationship to functional
renal failure (hepatorenal syndrome). J Hepatol 1986;3:1117.
[31] Llach J, Gines P, Arroyo V, et al. Eect of dipyridamole on kidney function in cirrhosis.
Hepatology 1993;17:5964.
[32] Lenz K. Hepatorenal syndrome: is it central hypovolemia, a cardiac disease, or part of gradually developing multiorgan dysfunction? Hepatology 2005;42:2635.
[33] Tsai M, Peng Y, Chen Y, et al. Adrenal insuciency in patients with cirrhosis, severe sepsis
and septic shock. Hepatology 2006;43:67381.
835
[34] Fernandez J, Escorsell A, Zabalza M, et al. Adrenal insuciency in patients with cirrhosis
and septic shock: eect of treatment with hydrocortisone on survival. Hepatology 2006;
44:128895.
[35] Guevara M, Fernandez-Esparrach G, Alessandria C, et al. Eects of contrast media on renal
function in patients with cirrhosis: a prospective study. Hepatology 2004;40:64651.
[36] Fasolato S, Angeli P, Dallagnese L, et al. Renal failure and bacterial infections in patients
with cirrhosis: epidemiology and clinical features. Hepatology 2007;45:2239.
[37] Terra C, Guevara M, Torre A, et al. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology 2005;
129:194453.
[38] Garcia-Tsao G, Sanyal A, Grace N, et al. Prevention and management of gastroesophageal
varices and variceal hemorrhage in cirrhosis. Hepatology 2007;46:92238.
[39] Duhamel C, Mauillon J, Berkelmans A, et al. Hepatorenal syndrome in cirrhotic patients:
terlipressine is a safe and ecient treatment; propranolol and digitalic treatments: precipitating and preventing factors? Am J Gastroenterol 2000;95:29845.
[40] Abraldes J, Tarantino I, Turnes J, et al. Hemodynamic response to pharmacological treatment of portal hypertension and long term prognosis of cirrhosis. Hepatology 2003;37:9028.
[41] Arroyo V, Terra C, Gine`s P. New treatments of hepatorenal syndrome. Semin Liver Dis
2006;26:25464.
[42] Moreau R, Lebrec D. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and
beyond. Hepatology 2006;43:38594.
[43] Turban S, Tuluvath P, Atta M. Hepatorenal syndrome. World J Gastroenterol 2007;13(30):
404655.
[44] Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in ascites: pathophysiological
basis of therapy and current management. J Hepatol 2003;38(Suppl 1):S6989.
[45] Cardenas A. Hepatorenal syndrome: a dreaded complication of end-stage liver disease. Am
J Gastroenterol 2005;100:18.
[46] Gine`s P, Cardenas A, Arroyo V, et al. Management of cirrhosis and ascites. N Engl J Med
2004;350:164654.
[47] Alessandria C, Jenon W, Marzano A, et al. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol
2002;14:13638.
[48] Fabrizi F, Dixit V, Martin P. Meta-analysis: terlipressine therapy for the hepatorenal
syndrome. Aliment Pharmacol Ther 2006;24:93544.
[49] Gines A, Salmeron JM, Gines P, et al. Oral misoprostol or intravenous prostaglandin E2 do
not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal
failure. J Hepatol 1993;17:2206.
[50] Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the
administration of midodrine and octreotide. Hepatology 1999;29:16907.
[51] Soper CP, Latif AB, Bending MR. Amelioration of hepatorenal syndrome with selective
endotheline-A antagonist. Lancet 1996;347:18423.
[52] Holt S, Goodier D, Marley R, et al. Improvement in renal function in hepatorenal syndrome
with N-acetylcysteine. Lancet 1999;353:2945.
[53] Wong F, Moore K, Dingemanse J, et al. Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome. Hepatology 2008;47:
1608.
[54] Gluud L, Kjaer M, Christensen E, et al. Terlipressin for hepatorenal syndrome. The
Cochrane Database of Systematic Reviews 2006;4:CD005162.
[55] Tandon P, Bain VG, Tsuyuki RT, et al. Systematic review: renal and other clinically relevant
outcomes in hepatorenal syndrome trials. Aliment Pharmacol Ther 2007;25:101728.
[56] Alessandria C, Ottobrelli A, Debernardi-Venon W, et al. Noradrenaline vs terlipressin in
patients with hepatorenal syndrome: a prospective randomized unblinded pilot study.
J Hepatol 2007;47:499505.
836
MUNOZ
837
[76] Salerno F, Camma C, Enea M, et al. Transjugular intrahepatic portosystemic shunt for
refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007;133:
82534.
[77] Shawcross D, Davies N, Mookerjee R, et al. Worsening of cerebral hyperemia by the administration of terlipressin in acute liver failure with severe encephalopathy. Hepatology 2004;
39:4715.
[78] Eefsen M, Dethlo T, Frederiksen HJ, et al. Comparison of terlipressin and noradrenalin on
cerebral perfusion, intracranial pressure and cerebral extracellular concentrations of lactate
and pyruvate in patients with acute liver failure in need of inotropic support. J Hepatol 2007;
47:3816.
[79] Davenport A, Will E, Davidson A. Improved cardiovascular stability during continuous
modes of renal replacement therapy in critically ill patients with acute hepatic and renal
failure. Crit Care Med 1993;21:32838.
[80] Demetriou A, Brown R, Busuttil R, et al. Prospective randomized multicenter controlled
trial of a bioarticial liver in treating acute liver failure. Ann Surg 2004;239:66070.
[81] Mitzner SR, Stange J, Klammt S, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of prospective, randomized, controlled clinical
trial. Liver Transpl 2000;6:27786.
[82] Rifai K, Ernst T, Kretschmer U, et al. The Prometheus device for extracorporeal support of
combined liver and renal failure. Blood Purif 2005;23:298302.
[83] Munoz SJ, Poordad F, Vierling J, et al. A new liver support device: rst results of a phase I clinical trial in patients with acute-on-chronic liver failure. Hepatology 2006;44(4 Suppl 1):695A.
[84] Nakae H, Igarashi T, Tajimi K, et al. A case report of hepatorenal syndrome treated with plasma
dialtration (selective plasma ltration with dialysis). Ther Apher Dial 2007;11(5):3915.
[85] Rimola A, Navasa M, Grande L, et al. Liver transplantation for patients with cirrhosis and
ascites. In: Gine`s P, Arroyo V, Rodes J, et al, editors. Ascites and renal dysfunction in liver
disease. Oxford (UK): Blackwell Publishing; 2005. p. 27185.
[86] Gonwa T, Morris C, Goldstein R, et al. Long term survival and renal function following liver
transplantation in patients with and without hepatorenal syndrome: experience in 300
patients. Transplantation 1991;51:42830.
[87] Gonwa T, Klintmalm G, Jennings L, et al. Impact of pretransplant renal function on survival
after liver transplantation. Transplantation 1995;59:3615.
[88] Cardenas A, Gine`s P. Management of complications of cirrhosis in patients awaiting liver
transplantation. J Hepatol 2005;42(Suppl 1):S12433.
[89] Ruiz R, Kunitake H, Wilkinson AH, et al. Long term analysis of combined liver and kidney
transplantation at a single center. Arch Surg 2006;141(8):73541.
[90] Ruiz R, Barri YM, Jennings LW, et al. Hepatorenal syndrome: a proposal for kidney after
liver transplantation (KALT). Liver Transpl 2007;13(6):83843.
[91] Davis CL, Feng S, Sung R, et al. Simultaneous liver-kidney transplantation: evaluation to
decision making. Am J Transpl 2007;7:17029.
[92] Sort P, Navasa M, Arroyo V, et al. Eect of intravenous albumin on renal impairment and
mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med
1999;5:4039.
[93] Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline improves short-term survival in severe
acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;
119:163748.
[94] Lebrec D, Thabut D, Oberti F, et al. Pentoxifylline for the treatment of patients with
advanced cirrhosis: a randomized placebo-controlled double blind trial. Hepatology 2007;
46:249A.
[95] Salerno F, Cazzaniga M, Gobbo G. Pharmacological treatment of hepatorenal syndrome:
a note of optimism. J Hepatol 2007;47:72931.